



RESEARCH HIGHLIGHT

Unconventional CD45RA⁺ memory CD8 T cells to control HIV infection during antiretroviral therapyMarion Rolot¹ and Benjamin G. Dewals² *Cellular & Molecular Immunology* (2020) 17:897–898; <https://doi.org/10.1038/s41423-020-0478-8>

Effective immune control of the viral reservoir during antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients is predominantly mediated by cellular immunity and CD8 T cells. In a recent work, Jin et al.¹ highlighted the direct role of unconventional CD45RA⁺PanKIR⁺EOMES⁺NKG2A^{+/-} memory T cells in the effective reduction in the latent viral reservoir during ART in HIV-infected patients. The authors nicely proposed a mechanism by which unconventional antigen-inexperienced memory CD8 T cells rather than antigen-specific CD8 T cells detect and kill reactivating HIV-infected cells through counter inhibition of HLA-I/KIR signaling.

Since its first description in the 1980s, great progress has been made in developing a treatment for HIV infection. Despite high efficiency in suppressing viremia and preventing transmission, ART is not curative and has to be taken for life.² Indeed, in the vast majority of cases, viral replication resumes if ART is discontinued due to the persistence of the viral reservoir. The retrovirus HIV-1 integrates its proviral genome into the host genome of infected target cells, such as activated CD4 T cells. Although most target CD4 T cells quickly die upon infection, a small proportion of these infected cells survive after having integrated the proviral DNA, which then persists indefinitely. Such a latent reservoir has a very slow decay, and as a consequence, treatment is unfortunately almost never curative.²

Evidence indicates that effector CD8 T cells, rather than antibodies, play a major role in the control of HIV-1 through the control of disease development and viral transmission.³ However, conventional viral-specific cytotoxic T cells (CTLs) might not be the only players in controlling the latent reservoir. Indeed, while conventional CTLs effectively limit viral burden in elite controllers, conventional HIV-specific CTL responses in ART patients cannot effectively eradicate latent reservoirs.^{4,5} Over the last decade, several studies in mice have comprehensively described the existence of an unconventional population of memory CD8 T cells that arise in response to environmental cues rather than antigen stimulation.⁶ This population of memory-phenotype CD8 T cells is antigen-inexperienced and is named innate or virtual memory CD8 T (CD8 T_{VM}) cells.⁷ CD8 T_{VM} cells display most of the functions of “true” or antigen-experienced memory cells, including increased effector capacities against pathogens, independent of the encounter with a specific antigen. While CD8 T_{VM} cell biology has been widely described in mice, studying antigen-inexperienced populations in humans is complicated by the nearly impossible task of controlling previous exposure to foreign

antigens such as pathogens. Nonetheless, there is evidence for the existence of “memory T cells with naive phenotype”, including CD45RA⁺ CD8 T cells displaying memory features.^{8,9} These cells have been described as CD45RA⁺ CD45RO⁻ CD27⁻ EOMES⁺ T-BET⁺ and/or NKG2A⁺ KIR2D⁺ KIR3DL1⁺.

Given the effector potential of CD8 T_{VM} cells, the study by Jin et al.¹ provides a thorough investigation of these unconventional memory-phenotype CD8 T cells and provides some important demonstrations that CD8 T_{VM} cells have an important role in the control of HIV infection in ART patients. A population of expanded unconventional CD45RA⁺PanKIR⁺ and/or NKG2A⁺ CD8 T cells was found to be present in HIV-infected individuals. These CD8 T_{VM} cells displayed increased levels of NK receptors, CD122, EOMES, and T-BET, lower levels of PD-1 and increased effector features, both cytotoxic and noncytotoxic. Although it is very difficult to be conclusive about the true identity of these CD8 T_{VM} cells, they nonetheless constitute a population of CD8 T lymphocytes with innate-like properties. This population was present in an increased number in HIV patients (treatment naive or receiving ART) compared to healthy controls and negatively correlated with HIV DNA and cell-associated unspliced RNA. Interestingly, the proportions of CD8 T_{VM} cells among total CD8 T cells positively correlated with both serum IL-15 and IFN- α 2 levels. While this finding might be anticipated from the characteristics of CD8 T_{VM} cells in mice, it suggests a reason for why some people develop those cells more steadily and potentially control HIV infection better than other patients. For example, we and others have shown that a history of infection, notably by helminths, can influence the proportion of CD8 T_{VM} cells in mice,¹⁰ but it is still unclear whether a similar mechanism exists in humans. How this population of CD8 T_{VM} cells develops in humans and therefore how it can be manipulated in the context of treatment or vaccination is of great interest.

Another important question concerns the mechanisms by which CD8 T_{VM} cells allow better control of viral infections. In this study, although showing responsiveness to HIV peptides, the CD8 T_{VM} cell population from ART patients was not specifically enriched with HIV-specific CD8 T_{VM} cells, consistent with innate-like and bystander functions of those cells. The capacity of CD8 T_{VM} cells to control HIV appeared to be inhibited by HLA-I/KIR signaling. However, it remains unclear whether these cells develop bystander defenses independently of virus-specific recognition or whether the control of HIV virus is regulated by virus-specific CD8 T_{VM} cells. Of course, both mechanisms could be present, and the population of CD8 T_{VM} cells described here could even show a

¹Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA and ²Immunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine-FARAH, University of Liège, Liège, Belgium
Correspondence: Benjamin G. Dewals (bgdewals@uliege.be)

Received: 15 May 2020 Accepted: 17 May 2020
Published online: 5 June 2020

certain heterogeneity worthy of further investigated. Given the existence of various mechanisms leading to the differentiation and/or expansion of CD8 T_{VM} cells, it is indeed expected that cells with different characteristics are included in this cell population.

The study by Jin et al.¹ added a substantial understanding of how CD8 T_{VM} cells might function in humans and added increasing evidence for an innate-like role of adaptive immune cells in humans. It appears that this particular population of CD8 T_{VM} has a strong potential to control the latent HIV reservoir and opens new perspectives on the potential for full clearance of latent HIV infection during ART. Given the importance of the CD8 T cell response in the control of HIV infection, this description of a role for CD8 T_{VM} cells is of great interest and could be exploited in the context of HIV cure. Although the global understanding of the origin, function and importance of unconventional CD8 T_{VM} cells against viral infections as well as in tumor development is growing, much needs to be done to fully understand the full impact of CD8 T_{VM} cells on health.

ADDITIONAL INFORMATION

Competing interests: The authors declare no competing interests.

REFERENCES

1. Jin, J.-H. et al. *Cell Mol. Immunol.* <https://doi.org/10.1038/s41423-020-0408-9> (2020).
2. Cohn, L. B., Chomont, N., Deeks, S. G., Biohub, C. Z. & Francisco, S. *Cell Host Microbe* **27**, 519–530 (2020).
3. Collins D. R., Gaiha G. D., Walker B. D. *Nat. Rev. Immunol.* <https://doi.org/10.1038/s41577-020-0274-9> (2020).
4. Keating, S. M. et al. *J. Acquir Immune Defic. Syndr.* **81**, 594–599 (2019).
5. Takata, H. et al. *Sci. Transl. Med.* <https://doi.org/10.1126/scitranslmed.aag1809> (2017).
6. Haluszczak, C. et al. *J. Exp. Med.* **206**, 435–448 (2009).
7. Lee, J. Y., Hamilton, S. E., Akue, A. D., Hogquist, K. A. & Jameson, S. C. *Proc. Natl Acad. Sci. USA* **110**, 13498–13503 (2013).
8. Quinn, K. M. et al. *Cell Rep.* **23**, 3512–3524 (2018).
9. Jacomet, F. et al. *Eur. J. Immunol.* **45**, 1926–1933 (2015).
10. Rolot, M. et al. *Nat. Commun.* **9**, 4516 (2018).